“Methadone treatment is proving to be the most efficient way to wean people in Bangladesh from addiction to buprenorphine, a pharmaceutical drug, and health experts say it should be expanded to reach thousands more drug users to prevent the spread of HIV,” IRIN reports. The news service notes that “illegal use of pharmaceutical substances, mostly buprenorphine, is on the rise” in the country. “Buprenorphine was intended to be used to wean injecting drug users, also known as people who inject drugs (PWID), from narcotics like heroin, but has itself become a substance of addiction, with users injecting a liquid form of it,” the news service notes, adding, “Methadone, a pain reliever, suppresses withdrawal symptoms and blocks craving.”
The Global Fund to Fight AIDS, Tuberculosis and Malaria and the Nigerian government on Friday “signed two grant agreements … worth a total of $225 million to support programs that will prevent and treat malaria,” a Global Fund press release reports. According to the press release, the agreements “include an additional $50 million for bed nets, approved in an unusual move by the Global Fund Board that was linked to additional commitments by the government of Nigeria” (8/24). Global Fund Deputy Executive Director Debrework Zewdie “told top government functionaries that the [money] is meant to assure the international community that Nigeria is a worthy partner in the fight to eradicate malaria,” ThisDay writes, adding, “During a transformation of the fund’s grant management structure this year, Nigeria was identified as one of the 20 ‘high impact’ countries that are now receiving special attention” (8/26). Aigboje Aig-Imoukhuede, CEO of Access Bank and chair of the Friends of the Global Fund Africa, “described the grant as [an] opportunity for Nigeria to show leadership and commitment in the fight against malaria by committing more resources to save lives,” the Daily Trust notes (Atonko, 8/26).
This post in the Center for Global Health Policy’s “Science Speaks” blog examines the use of stavudine, “also known as d4T, an antiretroviral treatment that was dropped in wealthy countries years ago and that the World Health Organization has recommended stop being included in treatment programs,” to treat HIV in Malawi. “[W]hile children and pregnant or breastfeeding women, as well as tuberculosis patients have access to less toxic treatments, stavudine continues to be the first treatment supplied to most Malawi patients under the terms of the country’s grant from the Global Fund to Fight AIDS, Tuberculosis and Malaria,” the blog writes, adding, “In a letter [.pdf] to Global Fund General Manager Gabriel Jaramillo and [U.S. Global AIDS Coordinator Ambassador] Eric Goosby, the Centre for Development of People (CEDEP), Health GAP (Global Access Project), and the Malawi Network of People Living with HIV/AIDS (MANET+) are asking the Global Fund to find a way to switch to first line treatment in Malawi that is acceptable to patients and World Health Organization standards” (8/15).
Aidspan, an independent watchdog of the Global Fund, on Wednesday published Issue 192 of its “Global Fund Observer.” The issue features an article examining new reports released by the Office of the Inspector General on three audits and four diagnostic reviews; an article highlighting two reports on the impact of the cancellation of Round 11 by the Global Fund; and an article discussing the reaction to Spain’s Global Fund contribution, among others (8/15).
IRIN reports on allegations that a grant from the Global Fund to Fight AIDS, Tuberculosis and Malaria to Uganda was misused. “Evidence of the mismanagement of a $51 million malaria grant to Uganda from the Global Fund resulted in the July arrest of three Ministry of Health employees and prompted a police investigation into the matter,” the news service writes, adding, “In September, the organization called for the refund of any ineligible expenses under the grant and the strengthening of safeguards to prevent future misappropriation of funds.”
In an article on the International HIV/AIDS Alliance’s webpage, the organization compares a new funding model adopted by the Global Fund to Fight AIDS, Tuberculosis and Malaria to its own “key principles” and “outline[s] how civil society is involved in refining the process of how money will be allocated.” The article addresses key elements of the new model as well as next steps leading up to the next Global Fund Board meeting in November (10/1).
“Although no official decision has been announced about whether to continue the … Affordable Medicines Facility-Malaria (AMFm), many of those familiar with it have told Nature that it must change or be phased out after this year,” the magazine reports in an article examining the future of the pilot program that distributes malaria drugs in seven African countries. “The AMFm aims to make artemisinin-based combination therapies (ACTs) readily available and affordable in malaria-ridden countries by relying on the free market for their distribution,” but “it is unclear how many of the drugs reached the pilot program’s target populations,” Nature writes. The magazine describes possible options for the program, and notes the Board of the Global Fund to Fight AIDS, Tuberculosis and Malaria will recommend a future path for the program at its meeting next month (Maxmen, 10/2).
“Zimbabwe is set to attain ‘universal’ coverage for AIDS treatment thanks in part to an $84 million disbursement [on Tuesday] by the United Nations-backed Global Fund to Fight AIDS, Tuberculosis and Malaria,” the U.N. News Centre reports (10/2). “The new disbursement will cover the cost of life-saving antiretroviral drugs (ARVs) for an additional 10,000 new patients, bringing the total number of people on treatment with Global Fund support to 203,440 by the end of the year,” the Global Fund announced in a press release. The funding also will support a six-month ARV buffer stock to prevent treatment interruptions for the 480,000 patients on therapy in Zimbabwe, the press release notes (10/2). The Global Fund’s announcement to support additional patients comes together with an announcement from PEPFAR to increase the number of patients supported by its program from 80,000 to 140,000, with a goal of having 160,000 patients on therapy by the end of next year, Zimbabwe’s Herald notes.
Negative Effects Of Global Health Initiatives On Developing Countries' Health Systems Exaggerated, Review Shows
“An evaluation of the scientific evidence on the effects of global health initiatives on the health systems of developing countries concludes that the harmful effects have been exaggerated,” according to a press release from the Royal Society of Medicine. The systematic review, published on Wednesday in JRSM Short Reports, “found that much of the research literature did not fulfill the requirements of rigorous scientific evidence,” according to the press release. “The systematic review identified 24 studies published in peer-reviewed scientific journals between 2002 and 2009 that have commented on adverse effects on health systems arising from investments by the Global Fund,” the press release states, adding, “All the studies evaluated contained only seemingly anecdotal evidence or authors’ perceptions or interpretations of circumstances” (10/24).
Researchers from Imperial College London, the Harvard Global Equity Initiative, and Harvard School of Public Health “have identified three global organizations that new funding initiatives should emulate in order to meet health priorities in poorer countries, in research published [Thursday] in the journal the Lancet,” Imperial College London reports in an article on its webpage. The study, “a comprehensive review of new funding methods that raised money for health in developing countries between 1990 and 2010 … found that the GAVI Alliance, … the Global Fund [to Fight AIDS, Tuberculosis and Malaria], and UNITAID, … were the sole organizations whose innovative financing methods had raised and distributed funds on a global scale,” the article notes, adding, “The authors concluded that innovative financing is essential to reduce dependence on contributions from donor governments. These innovative instruments provide a different way of raising money from new sources and making it available to address global health problems” (10/25).